Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : IVAX Insider Trading -- Ignore unavailable to you. Want to Upgrade?

To: Peter van Steennis who wrote (489)	1/25/1998 6:37:00 PM
From: 5,17,37,5,101,...	Read Replies (3) \| Respond to of 756

Your question is valid. Ivax is one of the top candidates on the list: 1) It has one of the highest cost structures. But after all of the required surgery, Ivax would be an enormous cash cow. 2) Frost has tried to sell twice and failed for reasons unknown to us. 3) It is selling now for a bargain basement price. Even a sale at $12 would be a bargain to a company acquiring. 4) Shareholders want out. They have no confidence in Frost. 5) Ivax has a good presence in international markets (including European respiratory unit and largest generic presence in UK). 6) Insiders have been buying indicating that they perceive value. Other drug company executives perceive the same value in Ivax and may be ready to pounce: 6a) Many drugs are scheduled to go off patent in the next three years making a presence in the generic market a necessity. 6b) A large drug company would be better able to market Ivax's products and better able to make their R&D productive. Wish I knew more, Jackson